PRODUCT INFORMATION



Vitamin K₁ 2,3-epoxide

Item No. 16017

CAS Registry No.: 25486-55-9

Formal Name: 1a,7a-dihydro-1a-methyl-7a-(3,7,11,15-

> tetramethyl-2-hexadecen-1-yl)naphth[2,3-b]oxirene-2,7-dione

Synonyms: 2,3-epoxy Phylloquinone,


Phylloquinone oxide, Vitamin K oxide

MF: $C_{31}H_{46}O_3$ FW: 466.7 **Purity:** ≥95% UV/Vis.: λ_{max} : 227 nm

A solution in ethanol Supplied as:

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Vitamin K₁ 2,3-epoxide is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of vitamin K_1 2,3-epoxide in these solvents is approximately 25 mg/ml.

Description

Vitamin K is a dietary nutrient essential for the normal biosynthesis of factors that are required for blood clotting. It has also been shown to inhibit cell growth. Vitamin K_1 2,3-epoxide is the inactive metabolite of vitamin K_1 . During clotting, vitamin K_1 is converted to this epoxide form and then rapidly reduced back to the vitamin by a microsomal epoxide reductase. This is referred to as the vitamin K epoxide cycle. 1 Certain anticoagulants target clotting factor synthesis by inhibiting the recycling of vitamin K1 from the inactive epoxide.1

Reference

1. Choonara, I.A., Malia, R.G., Haynes, B.P., et al. The relationship between inhibition of vitamin K₁ 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br. J. Clin. Pharmacol. 25(1), 1-7 (1988).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM